Puma Biotechnology (PBYI) Revenue (2017 - 2026)

Puma Biotechnology has reported Revenue for 10 years, with the latest figure at $44.8 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 2.59% year-over-year to $44.8 million; the trailing twelve-month figure through Mar 2026 stood at $227.2 million (down 2.38% YoY), and the FY2025 full-year result was $228.4 million, down 0.91% from the prior year.
• Revenue for Q1 2026 stood at $44.8 million, down from $75.5 million in the prior quarter.
• The five-year high for Revenue was $87.6 million in Q4 2022, with the low at $43.8 million in Q1 2024.
• Historically, Revenue has averaged $58.2 million across 5 years, with a median of $54.6 million in 2023.
• The largest YoY upside for Revenue was 58.33% in 2022 against a maximum downside of 53.41% in 2022.
• Puma Biotechnology's Revenue stood at $87.6 million in 2022, then fell by 17.65% to $72.2 million in 2023, then decreased by 18.15% to $59.1 million in 2024, then increased by 27.72% to $75.5 million in 2025, then plunged by 40.61% to $44.8 million in 2026.
• The last three Revenue figures came in at $44.8 million (Q1 2026), $75.5 million (Q4 2025), and $54.5 million (Q3 2025), per Business Quant data.